Publication: Significant progress has been made since the approval of the first CAR T-cell therapy, but there is still tremendous room for improvement.
Significant advancements in chimeric antigen receptor (CAR) T-cell therapy have occurred over the past several years as successful clinical trials and FDA approvals have positively impacted patient outcomes. Houston Holmes, MD, MBA, hematologist and medical oncologist at Texas Oncology–Baylor Charles A. Sammons Cancer Center shares the barriers and solutions to CAR-T therapy and what community oncologists do to optimize CAR T-cell therapy for their patients with cancer.
Read the full article at Targeted Oncology.